These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 34211840)
1. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report. Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE Front Oncol; 2021; 11():658327. PubMed ID: 34211840 [TBL] [Abstract][Full Text] [Related]
2. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859 [TBL] [Abstract][Full Text] [Related]
4. Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review. Durham C; Clemons M; Alias A; Konduri K Cureus; 2022 Jul; 14(7):e27223. PubMed ID: 36035049 [TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109 [TBL] [Abstract][Full Text] [Related]
6. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib. Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420 [TBL] [Abstract][Full Text] [Related]
7. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets. Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480 [TBL] [Abstract][Full Text] [Related]
8. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review. Liu X; Duan Y; Wang G; Zhu P Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390 [TBL] [Abstract][Full Text] [Related]
9. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma. Lim JJ; Chen EY; Schaub SK; Wagner MJ Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850 [TBL] [Abstract][Full Text] [Related]
10. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS Front Oncol; 2022; 12():761558. PubMed ID: 35237506 [TBL] [Abstract][Full Text] [Related]
11. Crizotinib in ALK Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567 [TBL] [Abstract][Full Text] [Related]
12. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015 [TBL] [Abstract][Full Text] [Related]
13. Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT). Sommer S; Schmutz M; Schaller T; Mayr P; Dintner S; Märkl B; Huss R; Golas MM; Kuhlen M; Jordan F; Claus R; Heinrich B Cancer Rep (Hoboken); 2024 Jan; 7(1):e1916. PubMed ID: 37950626 [TBL] [Abstract][Full Text] [Related]
14. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma. Parker BM; Parker JV; Lymperopoulos A; Konda V J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review. Styczewska M; Patel A; Jaskulowska J; Godzinski J; Swieton D; Wasag B; Dass J; Bien E; Krawczyk MA Anticancer Drugs; 2021 Nov; 32(10):1111-1115. PubMed ID: 34145176 [TBL] [Abstract][Full Text] [Related]
16. Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT). Ingley KM; Hughes D; Hubank M; Lindsay D; Plumb A; Cox R; Chesler L; Strauss SJ Lung Cancer; 2021 Aug; 158():151-155. PubMed ID: 34059352 [TBL] [Abstract][Full Text] [Related]
17. A recurrent inflammatory myofibroblastic tumor patient with two novel Xu X; Li L; Zhang Y; Meng F; Xie H; Duan R Transl Cancer Res; 2022 Sep; 11(9):3379-3384. PubMed ID: 36237256 [TBL] [Abstract][Full Text] [Related]